RS52710B - Treatment of cartilage disorders with fgf-18 - Google Patents

Treatment of cartilage disorders with fgf-18

Info

Publication number
RS52710B
RS52710B RS20120483A RSP20120483A RS52710B RS 52710 B RS52710 B RS 52710B RS 20120483 A RS20120483 A RS 20120483A RS P20120483 A RSP20120483 A RS P20120483A RS 52710 B RS52710 B RS 52710B
Authority
RS
Serbia
Prior art keywords
fgf
treatment
cartilage disorders
administered
compound
Prior art date
Application number
RS20120483A
Other languages
Serbian (sr)
Inventor
Alberto Gimona
Christoph H. Ladel
Elmar Vom Baur
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Priority claimed from PCT/EP2007/058830 external-priority patent/WO2008023063A2/en
Publication of RS52710B publication Critical patent/RS52710B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Abstract

FGF-18 jedinjenje za upotrebu u terapiji poremećaja hrskavice naznačeno time da to FGF-18 jedinjenje treba da se daje najmanje 3 uzastopne nedelje po terapijskom ciklusu, a ova davanja se primenjuju u razmacima od oko najmanje 6, 7 ili 8 dana.Prijava sadrži još 14 patentnih zahteva.The FGF-18 compound for use in the treatment of cartilage disorder wherein the FGF-18 compound is to be administered for at least 3 consecutive weeks per treatment cycle, and these administrations are administered at intervals of at least 6, 7 or 8 days. 14 patent claims.

RS20120483A 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18 RS52710B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06119557 2006-08-25
US84060006P 2006-08-28 2006-08-28
PCT/EP2007/058830 WO2008023063A2 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18

Publications (1)

Publication Number Publication Date
RS52710B true RS52710B (en) 2013-08-30

Family

ID=37684849

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120483A RS52710B (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18

Country Status (11)

Country Link
CN (1) CN101505787B (en)
BR (1) BRPI0715728A8 (en)
DK (1) DK2054050T3 (en)
ES (1) ES2392883T3 (en)
MY (1) MY148277A (en)
NZ (1) NZ574216A (en)
PT (1) PT2054050E (en)
RS (1) RS52710B (en)
SI (1) SI2054050T1 (en)
UA (1) UA99818C2 (en)
ZA (1) ZA200900426B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023703A1 (en) * 2012-08-06 2014-02-13 Ares Trading S.A. Genetic markers for predicting responsiveness to fgf-18 compound
SG11201606697YA (en) * 2014-02-20 2016-09-29 Merck Patent Gmbh Implant comprising fgf-18
RU2682159C2 (en) * 2014-02-20 2019-03-15 Мерк Патент Гмбх Fgf-18 in transplantation and tissue engineering procedures
PT3107559T (en) * 2014-02-20 2018-10-31 Merck Patent Gmbh Fgf-18 compound dosing regimen
US20180000736A1 (en) * 2015-01-08 2018-01-04 University Of Iowa Research Foundation Methods for the regeneration of articular cartilage in vivo
US11020454B2 (en) 2015-07-15 2021-06-01 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
AU2016306626A1 (en) * 2015-08-13 2018-02-22 Merck Patent Gmbh Combination composition comprising FGF-18 compound
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN117721115A (en) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 mRNA for treating osteoarthritis and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
CA2592044A1 (en) * 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
AU2005314438B2 (en) * 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts

Also Published As

Publication number Publication date
SI2054050T1 (en) 2012-12-31
NZ574216A (en) 2011-11-25
MY148277A (en) 2013-03-29
DK2054050T3 (en) 2012-09-03
CN101505787B (en) 2013-09-04
BRPI0715728A2 (en) 2013-09-17
CN101505787A (en) 2009-08-12
ES2392883T3 (en) 2012-12-14
BRPI0715728A8 (en) 2018-04-03
PT2054050E (en) 2012-09-17
UA99818C2 (en) 2012-10-10
ZA200900426B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
RS52710B (en) Treatment of cartilage disorders with fgf-18
HRP20110861T1 (en) Drug for treatment of influenza
UA108832C2 (en) COMBINATIONS OF ANTI-HER2-ANTIBLE-MEDICINAL CONJUGATES AND CHEMOTHERAPEUTICS
RS54372B1 (en) Collagenase for treating cellulite
EA201100765A1 (en) Long-term circulation nanoparticles
EA200970575A1 (en) COMPOUNDS ON THE BASIS OF 4-PHENYL-6- (2,2,2-TRIFTOR-1-PHENYLETOXI) Pyrimidine and methods for their use
DK1970059T3 (en) Calcium dobesilate drug for the treatment and prophylaxis of tendon disorders
BRPI0418384A (en) pharmaceutical compositions and methods for inhibiting fibrous adhesions using various agents
MX346335B (en) Antisense compositions and methods of making and using same.
MX2009013676A (en) Methods and compositions to inhibit edema factor and adenylyl cyclase.
CR10166A (en) USE OF BENZO-FUSION HETEROCICLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF BIPOLAR DISORDER AND MANIA
BR112014032239A2 (en) inhibitors of the micro-rnas mir-15 family
ATE489371T1 (en) BENZAMIDE GLUCOCINASE ACTIVATORS
EP1907014A4 (en) Chondrogenic compositions and methods of use
MY155633A (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
RS52251B (en) Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants
MX2010001849A (en) Cyclic depsipeptides.
RS52821B (en) Long term treatment of hiv- infection with tcm278
RS54265B1 (en) Methods for treating adhesive capsulitis
MX2009005114A (en) Use of gabapentin and pregabalin prodrugs for treating tinnitus.
JO3676B1 (en) Pharmaceutical compositions comprising modified fucans and methods relating thereto
ATE530188T1 (en) COMPOSITIONS AND METHODS FOR DELIVERING ANTI-CANCER AGENTS
ATE538799T1 (en) COMPOSITIONS FOR TREATING HAIR LOSS
NZ609440A (en) Preventative or therapeutic agent for fibrosis
BR112012006070A2 (en) compositions and methods for treating seizure disorders.